title: Infliximab therapy for refractory uveitis: 2-year results of a prospective trial.
authors.forename: Eric B
authors.initials: EB
authors.lastname: Suhler
authors.forename: Justine R
authors.initials: JR
authors.lastname: Smith
authors.forename: Tracy R
authors.initials: TR
authors.lastname: Giles
authors.forename: Andreas K
authors.initials: AK
authors.lastname: Lauer
authors.forename: Michael S
authors.initials: MS
authors.lastname: Wertheim
authors.forename: Daryl E
authors.initials: DE
authors.lastname: Kurz
authors.forename: Paul A
authors.initials: PA
authors.lastname: Kurz
authors.forename: Lyndell
authors.initials: L
authors.lastname: Lim
authors.forename: Friederike
authors.initials: F
authors.lastname: Mackensen
authors.forename: Terri D
authors.initials: TD
authors.lastname: Pickard
authors.forename: James T
authors.initials: JT
authors.lastname: Rosenbaum
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab